<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00351871</url>
  </required_header>
  <id_info>
    <org_study_id>P03851</org_study_id>
    <nct_id>NCT00351871</nct_id>
  </id_info>
  <brief_title>Influence of Marker of Insulin Resistance Upon Hepatitis C Virus (HCV) Treatment Responses to PEG Intron and Rebetol Therapy</brief_title>
  <official_title>Influence of Marker of Insulin Resistance Upon HCV Treatment Responses to PEG Intron and Rebetol Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Louisiana State University Health Sciences Center in New Orleans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Louisiana State University Health Sciences Center in New Orleans</source>
  <brief_summary>
    <textblock>
      The objective of this study is to better understand the influence of insulin resistance upon&#xD;
      treatment response in hepatitis C virus treated with PEG Intron and Rebetol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The relationship between HCV and IR is an evolving one. This study will allow a more formal&#xD;
      evaluation of this relationship. Four hundred patients will be treated using weight based Peg&#xD;
      Intron and Rebetol. Clinical and biochemical data related to IR will be collected to&#xD;
      determine if any such factors can predict who will have a sustained virological response. To&#xD;
      evaluate patients for insulin resistance, the HOMA score (the product of the fasting insulin&#xD;
      level and blood glucose level), waist circumference, and body mass index will be measured.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in treatment response rates between those with insulin resistance those without.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Which marker of Insulin Resistance (i.e. the HOMA score, Waste Circumference or BMI) is the best measure for risk of hypo responsiveness.</measure>
  </secondary_outcome>
  <enrollment type="Actual">400</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-Intron Plus REBETOL</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Evidence of chronic hepatitis C infection (viremia) by RT-PCR superquantitative&#xD;
&#xD;
          -  HCV Genotype 1&#xD;
&#xD;
          -  Liver biopsy within 36 months of enrollment consistent with chronic hepatitis&#xD;
&#xD;
          -  Compensated liver disease with laboratory parameters at entry visit as follows:&#xD;
&#xD;
               -  Hemoglobin values of &gt; 12 gm/dL&#xD;
&#xD;
               -  WBC &gt; 2,500/mm3&#xD;
&#xD;
               -  Neutrophil count &gt; 1,000/mm3&#xD;
&#xD;
               -  Platelets &gt; 100,000/mm3&#xD;
&#xD;
               -  Prothrombin time &lt; 2 seconds prolonged compared to control, or equivalent INR&#xD;
                  ratio&#xD;
&#xD;
          -  Bilirubin within 20% of the upper limit of normal unless non-hepatitis related factors&#xD;
             exists such as Gilbert's syndrome.&#xD;
&#xD;
          -  Albumin &gt; 3.0 g/dL&#xD;
&#xD;
          -  Serum creatinine &lt; 1.4 mg/dL&#xD;
&#xD;
          -  Normal thyroid stimulating hormone (TSH) or thyroid disease clinically controlled&#xD;
&#xD;
          -  Antinuclear antibodies (ANA)&lt; 1:160&#xD;
&#xD;
          -  FBS &lt; 126 mg/dl&#xD;
&#xD;
          -  No significant co-existing psychiatric disease&#xD;
&#xD;
          -  Free from substance abuse for past 2 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment for HCV.&#xD;
&#xD;
          -  Evidence of being HIV positive.&#xD;
&#xD;
          -  Hypersensitivity to alpha interferon, Peg Intron or Rebetol.&#xD;
&#xD;
          -  Any other causes for chronic liver disease other than chronic hepatitis C besides&#xD;
             obesity.&#xD;
&#xD;
          -  Hemoglobinopathies (e.g., Thalassemia) or any other cause of hemolytic anemia.&#xD;
&#xD;
          -  Evidence of advanced liver disease such as a history of or presence of ascites,&#xD;
             bleeding varices, or hepatic encephalopathy.&#xD;
&#xD;
          -  Preexisting medical condition that could interfere with the patient's participation in&#xD;
             the protocol including: CNS trauma or active seizure disorders requiring medication;&#xD;
             diabetes mellitus; serious pulmonary disease; immunologically mediated diseases; gout&#xD;
             attack within 12 months; or any medical condition requiring, or likely to require&#xD;
             during the course of the study, chronic systemic administration of steroids.&#xD;
&#xD;
          -  Patients with evidence of ischemia on stress testing, an arrhythmia, cardiac failure,&#xD;
             coronary surgery, uncontrolled hypertension, angina or a myocardial infarction within&#xD;
             12 months.&#xD;
&#xD;
          -  Patients with a history of organ transplantation will be excluded.&#xD;
&#xD;
          -  Patients taking insulin sensitizing drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William M. Cassidy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Louisiana State University Health Sciences Center</affiliation>
  </overall_official>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>July 12, 2006</study_first_submitted>
  <study_first_submitted_qc>July 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2006</study_first_posted>
  <last_update_submitted>February 3, 2009</last_update_submitted>
  <last_update_submitted_qc>February 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2009</last_update_posted>
  <keyword>HCV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

